EGFR and cancer: Several reports have identified neuregulin ligands as potential endogenous factor that allows the activation of specific components of EGFR family such as ErbB3 [29–31] and over expression of ErbB3 has been frequently detected in a variety of cancers, including those of the breast, colon, stomach, ovary, pancreas and brain [19, 32–37].